二甲双胍：衰老研究中的一个充满希望的前景。
Metformin: A Hopeful Promise in Aging Research.
作者信息
Novelle Marta G, Ali Ahmed, Diéguez Carlos, Bernier Michel, de Cabo Rafael
机构信息
Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, Maryland 21224 Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, Maryland 21224.
出版信息
Cold Spring Harb Perspect Med. 2016 Mar 1;6(3):a025932. doi: 10.1101/cshperspect.a025932.
Even though the inevitable process of aging by itself cannot be considered a disease, it is directly linked to life span and is the driving force behind all age-related diseases. It is an undisputable fact that age-associated diseases are among the leading causes of death in the world, primarily in industrialized countries. During the last several years, an intensive search of antiaging treatments has led to the discovery of a variety of drugs that promote health span and/or life extension. The biguanide compound metformin is widely used for treating people with type 2 diabetes and appears to show protection against cancer, inflammation, and age-related pathologies. Here, we summarize the recent developments about metformin use in translational aging research and discuss its role as a potential geroprotector.
尽管衰老这一不可避免的过程本身不能被视为一种疾病，但它与寿命直接相关，并且是所有与年龄相关疾病的驱动力。与年龄相关的疾病是世界上主要的死亡原因之一，在工业化国家尤为如此，这是一个无可争议的事实。在过去几年中，对抗衰老治疗的深入研究导致发现了多种促进健康寿命和/或延长寿命的药物。双胍类化合物二甲双胍被广泛用于治疗2型糖尿病患者，并且似乎对癌症、炎症和与年龄相关的病理状况具有保护作用。在此，我们总结了二甲双胍在转化衰老研究中的最新进展，并讨论了其作为潜在老年保护剂的作用。
Zotero 插件